Charles River Laboratories reinforced its commitment to strengthening the Asia Pacific biomanufacturing ecosystem by signing a series of strategic Memorandums of Understanding during the APAC Biomanufacturing Leadership Summit 2026.
The agreements were signed with NSG Bio, Locus Cell Co Ltd Taiwan, and Taiwan Bio Manufacturing Corporation, reflecting a shared ambition to expand collaboration across the region’s rapidly growing biologics and advanced therapy landscape.
The partnerships are expected to support deeper engagement across the biologics development value chain, including research, manufacturing innovation, and technical collaboration. By aligning capabilities with regional biotechnology companies and manufacturing organisations, Charles River aims to help accelerate the development and commercialisation of next generation therapeutics.
Asia Pacific is increasingly emerging as a critical hub for global biopharmaceutical innovation. Governments across the region are investing in biotechnology infrastructure, advanced manufacturing capabilities, and talent development to support a growing pipeline of biologics, cell therapies, and gene therapies. Strategic collaborations between global service providers and regional biotechnology leaders are therefore becoming essential to support this expanding ecosystem.
Through these agreements, Charles River will work with its partners to explore opportunities in preclinical research support, process development, and advanced biomanufacturing capabilities. The collaborations are expected to strengthen technology exchange and enable companies in the region to move promising therapeutic programmes more efficiently from discovery through development and into manufacturing.
NSG Bio brings expertise in biologics development and manufacturing support, while Locus Cell Co Ltd Taiwan is advancing innovative cell based therapeutic platforms. Taiwan Bio Manufacturing Corporation contributes strong capabilities in large scale biopharmaceutical manufacturing infrastructure. Together, these organisations represent key pillars of the region’s expanding biotechnology and biomanufacturing landscape.
The partnerships also highlight the increasing role of cross border collaboration in enabling global competitiveness in biopharmaceutical manufacturing. As therapeutic modalities become more complex, companies must integrate research, development, manufacturing, and regulatory capabilities across multiple regions.
The signing of these MOUs during the summit underscores the importance of industry platforms that bring together biotechnology innovators, manufacturing leaders, investors, and policymakers to strengthen the global biopharmaceutical value chain.
By fostering strategic collaboration and knowledge exchange, the APAC Biomanufacturing Leadership Summit 2026 continues to play a key role in supporting the development of advanced biomanufacturing capabilities across the region and positioning Asia Pacific as a vital node in the global life sciences ecosystem.
